Further investigation of the regulated immuno-metabolic and senescence pathways showed how plasma expression of APOE differentiates ALS patients based on rate of disease progression, while the study of other biomarkers like ITGB3, Galectin-3 and TGFB1 confirmed the pattern of regulation across WT and SOD1G93A transgenic animal models seen in the proteomic experiment. The gene discussed is LGALS3; the disease is amyotrophic lateral sclerosis.